The purpose of this study is to determine - whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms - whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg


  1. 12/11/13 12/11/13 - Martin Dugas
  2. 8/21/15 8/21/15 - Martin Dugas
Uploaded on

December 11, 2013


To request one please log in.


Creative Commons BY-NC 3.0 Legacy

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00099502 Multiple Sclerosis


  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion criteria
Female and male patients
Aged 18-55 years
Diagnosis of RRMS (Relapsing-Remitting Multiple Sclerosis)
EDSS score of 0 to 5.0
Treatment-naive to IFNB or Copaxone
Exclusion criteria
Neurological progression at disease onset or between relapses
Serious or acute heart diseases
History of severe depression or suicide attempt
Serious or acute liver, renal or bone marrow dysfunction
Monoclonal gammopathy
Known allergy to Gadolinium-DTPA, to IFNs (Interferons), to glatiramer acetate, to human albumin or to mannitol
Pregnancy or lactation
Medical Concepts

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial